drugset / Trial / NCT01596088

A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

NCT01596088

Phase 1/2 Completed 2 enrolled Kissei Pharmaceutical Co., Ltd.
Open-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KDX-0811(Dexrazoxane) in the treatment of accidental extravasation of anthracycline anti-cancer agents.

Timeline

Start
Primary completion
2014-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexrazoxane Small molecule 1000 mg/m2